A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options

J Clin Pathol. 2015 Dec;68(12):1044-6. doi: 10.1136/jclinpath-2015-202996. Epub 2015 Sep 18.
No abstract available

Keywords: CANCER; COLORECTAL CANCER; MONOCLONAL ANTIBODY.

Publication types

  • Case Reports

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • CHO Cells
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / surgery
  • Cricetinae
  • Cricetulus
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Liver Neoplasms / secondary
  • Lung Neoplasms / secondary
  • Middle Aged
  • Receptor, ErbB-2 / immunology*
  • Remission Induction
  • Trastuzumab / therapeutic use*

Substances

  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab